Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study

Abstract

<h3>Objectives</h3><p>Epidermal growth factor receptor (<em>EGFR</em>) mutations (<em>EGFR</em>m) are common oncogene drivers in non-small cell lung cancer (NSCLC). This real-world study explored treatment patterns and time to receive <em>EGFR</em>m test results in patients with advanced <em>EGFR</em>m NSCLC.</p><h3>Methods</h3><p>A cross-sectional medical chart review was completed May–August 2020 in Australia, Canada, Germany, Italy, South Korea, Taiwan, UK, and USA. Eligible patients had advanced NSCLC and a positive <em>EGFR</em>m test result January–December 2017. Data were abstracted from NSCLC diagnosis to end of follow-up (31 March 2020) or patient’s death whichever occurred earlier. The index date was the date of <em>EGFR</em>m confirmation.</p><h3>Results</h3><p>223 physicians provided data for 1,793 patients. Patients’ mean age was 64.7 years, 54 % were male, 30.7 % had no history of smoking. Overall, 78 % of <em>EGFR</em>m test results were received ≤ 2 weeks after request (range of median 7–14 days across countries). Median time from advanced NSCLC diagnosis to <em>EGFR</em>m test result was 18 days (median range 10–22 days across countries). Over a third (37 %) of patients received a systemic treatment prior to <em>EGFR</em>m result; chemotherapy (25 %) and EGFR-TKI (15 %) were most commonly prescribed; post-<em>EGFR</em> test-result was EGFR-TKI (68 %); 80 % of patients initiated EGFR-TKI at any time point post-NSCLC diagnosis. Of those receiving a first-line EGFR-TKI post-<em>EGFR</em>m testing, 84 % received a TKI alone, 12 % in combination with chemotherapy, and 3 % with other treatments. Median time from first-line EGFR-TKI initiation post-<em>EGFR</em>m testing to first subsequent treatment was 19.8 months.</p><h3>Conclusion</h3><p>Over one-fifth of patients wait >14 days for their <em>EGFR</em>m test results, affecting their likelihood of receiving first-line EGFR-TKI with 20 % of patients never receiving EGFR TKI treatment. There was significant inter-country variability in the proportion of patients receiving EGFR TKIs. Our study highlights the need to improve <em>EGFR</em>m testing turnaround times and treatment initiation across countries.</p>